홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /반응

Trifluoroacetic acid → 4-[7-(3-[1,2,4]Triazol-4-yl-propoxy)-quinazolin-4-yl]-piperidine-1-carboxylic acid (6-morpholin-4-yl-pyridin-3-yl)-amide

HRID 657259
인쇄

반응식

HRID 657259 반응식
[C:1]([O:5][C:6]([N:8]1[CH2:13][CH2:12][CH:11]([C:14]2[C:23]3[C:18](=[CH:19][C:20]([O:24][CH2:25][CH2:26][CH2:27][N:28]4[CH:32]=[N:31][N:30]=[CH:29]4)=[CH:21][CH:22]=3)[N:17]=[CH:16][N:15]=2)[CH2:10][CH2:9]1)=[O:7])([CH3:4])([CH3:3])[CH3:2].[C:33](O)([C:35]([F:38])(F)F)=O.[Al].CN(CCO)C.Cl.[N+](C1C=CC(OC(=O)[NH:59][C:60]2[CH:61]=[N:62][C:63]([N:66]3[CH2:71][CH2:70][O:69][CH2:68][CH2:67]3)=[CH:64][CH:65]=2)=CC=1)([O-])=O>C(Cl)(Cl)Cl>[N:66]1([C:63]2[N:62]=[CH:61][C:60]([NH:59][C:6]([N:8]3[CH2:13][CH2:12][CH:11]([C:14]4[C:23]5[C:18](=[CH:19][C:20]([O:24][CH2:25][CH2:26][CH2:27][N:28]6[CH:32]=[N:31][N:30]=[CH:29]6)=[CH:21][CH:22]=5)[N:17]=[CH:16][N:15]=4)[CH2:10][CH2:9]3)=[O:7])=[CH:65][CH:64]=2)[CH2:71][CH2:70][O:69][CH2:68][CH2:67]1.[C:1]([O:5][C:6]([N:8]1[CH2:13][CH2:12][CH:11]([C:14]2[C:23]3[C:18](=[CH:19][C:35]([F:38])=[CH:33][CH:22]=3)[N:17]=[CH:16][N:15]=2)[CH2:10][CH2:9]1)=[O:7])([CH3:4])([CH3:3])[CH3:2]
참가 물질반응 조건실험 절차후처리출처 및 근거반응 노트

참가 물질

8

반응물 5

HCID 6422Trifluoroacetic acidHCID 79022-(Dimethylamino)ethanolHCID 5359268AluminumHCID 595517624-[7-(3-[1,2,4]Triazol-4-yl-propoxy)-quinazolin-4-yl]-piperidine-1-carboxylic acid tert-butyl esterHCID 69259253(6-Morpholin-4-yl-pyridin-3-yl)-carbamic acid-4-nitrophenyl ester hydrochloride

생성물 2

HCID 58770718
4-[7-(3-[1,2,4]Triazol-4-yl-propoxy)-quinazolin-4-yl]-piperidine-1-carboxylic acid (6-morpholin-4-yl-pyridin-3-yl)-amide
HCID 595517364-(7-Fluoro-quinazolin-4-yl)-piperidine-1-carboxylic acid tert-butyl ester

시약·촉매·용매 1

HCID 6212Chloroform용매

반응 조건

온도
40 °C

실험 절차

The crude 4-[7-(3-[1,2,4]Triazol-4-yl-propoxy)-quinazolin-4-yl]-piperidine-1-carboxylic acid tert-butyl ester, as prepared in the previous step, was treated with TFA (70 μL) at 100° C. in a sealed vial for 10 min (aluminum block). CHCl3 (450 μL) and DMEA (140 μL, 1.3 mmol) were added, and one-half of the resulting homogeneous amber solution was treated with (6-morpholin-4-yl-pyridin-3-yl)-carbamic acid-4-nitrophenyl ester hydrochloride (22 mg, 58 μmol), as prepared in Example 80a, and stirred at 40° C. for 1.5 hr. (The other one-half of the homogenous solution was diverted to the synthesis given in Example 114.) The reaction was then partitioned with 2M K2CO3 (2 mL) and DCM (2 mL), and the aqueous layer was extracted with 9:1 DCM/MeOH (1×2 mL). The combined organic layers were concentrated and the residue was partially purified with a 5 g silica flash cartridge (97:3 acetone/MeOH eluent with 2% DMEA), and further purified with HPLC (C18 column) to provide the title compound as a powder after lyophilization [2.1 mg, 8.1% overall from 4-(7-fluoro-quinazolin-4-yl)-piperidin-1-carboxylic acid tert-butyl ester.] 1H-NMR (400 MHz, 95:5 CDCl3/CD3OD) δ 9.12 (s, 1H), 8.43 (dd, 1H), 8.30 (br s, 2H), 8.13 (m, 2H), 7.32 (m, 1H), 7.26 (dd, 1H), 6.96 (d, 1H), 4.37 (m, 4H), 4.21 (t, 2H), 3.88 (m, 4H), 3.75 (m, 1H), 3.59 (m, 4H), 3.14 (m, 2H), 2.42 (pentet, 2H), 2.16-1.95 (m, 4H). LC/MS (ESI) calcd mass 543.3, found 544.1 (MH)+.

후처리

  1. customas prepared in Example 80a
  2. custom) The reaction was then partitioned with 2M K2CO3 (2 mL) and DCM (2 mL)
  3. extractionthe aqueous layer was extracted with 9:1 DCM/MeOH (1×2 mL)
  4. concentrationThe combined organic layers were concentrated
  5. customthe residue was partially purified with a 5 g silica flash cartridge (97:3 acetone/MeOH eluent with 2% DMEA)
  6. customfurther purified with HPLC (C18 column)

출처 및 근거

ORD 기록
ord-8bee2a3e66ba4845bd52c1ca64defbc7
출처 데이터셋
uspto-grants-2011_12
DOI
10.6084/m9.figshare.5104873.v1
특허 번호
US08071768B2

반응 노트

이 페이지에서참가 물질반응 조건실험 절차후처리출처 및 근거반응 노트